Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz", Madrid, Spain.
Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz", Madrid, Spain.
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):435-438. doi: 10.1016/j.bbcan.2017.08.005. Epub 2017 Sep 12.
The functional inhibition of protein phosphatase 2A (PP2A) has emerged in the last years as a common alteration in breast cancer that determines poor outcome and contributes to disease progression and aggressiveness. Furthermore, expression of estrogen receptor (ER) is a high relevant molecular event with key therapeutic implications in breast cancer, and androgen receptor (AR) signaling is involved in the pathogenesis of breast cancer and represents a novel target with crescent importance in this disease. In this review, we summarize the role of the tumor suppressor PP2A in modulating ER and AR signaling in breast cancer, the molecular mechanisms involved, and its biological and therapeutic impact.
近年来，蛋白磷酸酶 2A（PP2A）的功能抑制已成为乳腺癌的一种常见改变，它决定了不良预后，并促进疾病进展和侵袭性。此外，雌激素受体（ER）的表达是乳腺癌中具有关键治疗意义的一个重要分子事件，而雄激素受体（AR）信号转导参与了乳腺癌的发病机制，并且是该疾病中一个新的具有日益重要意义的靶点。在这篇综述中，我们总结了肿瘤抑制因子 PP2A 在调节乳腺癌中 ER 和 AR 信号转导中的作用、涉及的分子机制，以及其生物学和治疗学意义。
